EyePoint (EYPT) vs Fulcrum Therapeutics (FULC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fulcrum Therapeutics (FULC) has outperformed EyePoint (EYPT) over the past year, losing 60.3% versus a loss of 74.9%. Over five years, EYPT leads with a -71.0% price change compared with -85.9% for FULC. Fulcrum Therapeutics is the larger company by market cap ($281.9 million vs $277.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EYPT | FULC |
|---|---|---|
| Share price | $3.31 | $3.70 |
| Market cap | $277.51M | $281.92M |
| 1-day change | -0.30% | +0.68% |
| YTD return | -81.83% | -67.55% |
| 1-year return | -74.94% | -60.28% |
| 5-year return | -70.98% | -85.88% |
| EPS (TTM) | $-3.75 | $-1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.11 | $15.74 |
| 52-week low | $3.05 | $2.83 |
| Distance from 52-week high | -82.68% | -76.52% |
| Analyst consensus | none | none |
| Avg. price target upside | +682.78% | -0.68% |
| Average volume | 3.93M | 1.53M |
| Shares outstanding | 83.84M | 76.30M |
| Employees | 214 | 9 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FULC has outperformed EYPT by 14.7 percentage points over the past year.
- The two companies sit in different sectors: EyePoint in Industrials and Fulcrum Therapeutics in Health Care.
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
EYPT vs FULC FAQ
Which is bigger, EyePoint or Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $281.92M compared with $277.51M for EyePoint (EYPT).
Which stock has performed better over the past year, EYPT or FULC?
FULC returned -60.28% over the past 12 months, compared with -74.94% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are EyePoint and Fulcrum Therapeutics in the same industry?
No. EyePoint is in the Industrials sector, while Fulcrum Therapeutics is in Health Care.